HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAsafety guidance66% confidence

FDA AP — OXYCODONE AND ASPIRIN (SUPPL)

Source: FDA

Why This Matters

Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as Sun Pharma; the same agency is already in play for this signal, so precedent weight is higher.

Regulatory Analysis

Application ANDA040255. Sponsor: ANI PHARMS. Submission status: AP. Submission type: SUPPL. Active ingredients: ASPIRIN, OXYCODONE HYDROCHLORIDE, OXYCODONE TEREPHTHALATE.

Supporting Context

Therapeutic area
Pain Management · Opioid Combination
Sub-indication
Pain

Related signal: FDA Approval Letter for Oxycodone and Aspirin Combination

Source

View source document

Related Signal

Open signal — FDA Approval Letter for Oxycodone and Aspirin Combination
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.